Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.
about
Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in JapanCrohn's disease in womenUveitis and gender: the course of uveitis in pregnancyManagement of inflammatory bowel disease in pregnancySafety of TNF-α inhibitors during IBD pregnancy: a systematic reviewUse of the tumor necrosis factor-blockers for Crohn's diseaseAnti-inflammatory and immunosuppressive drugs and reproductionReview article: Infliximab therapy for inflammatory bowel disease--seven years onHuman pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing dataConsiderations on biologic agents in psoriasis with the new pregnancy lactation labeling rule.Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient.Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy.Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.Treating rheumatic diseases in pregnancy: dos and don'tsFertility and pregnancy in the patient with inflammatory bowel disease.Risks and benefits of biologic therapy for inflammatory bowel diseases.Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study.A meta-analysis on the influence of inflammatory bowel disease on pregnancy.A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel diseaseTherapy insight: drugs for gastrointestinal disorders in pregnant women.Current opinion on treatment of inflammatory bowel disease in pregnant women.Drug therapy of inflammatory bowel disease in fertile women.Dermatologic treatment during pregnancy: practical overview.Safety of biologic therapy.Effects and treatment of inflammatory bowel disease during pregnancyTumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel diseasePregnancy and breastfeeding in patients with Crohn's disease.Management of inflammatory bowel disease in the pregnant patient.Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding.Arthritis in pregnancy: the role and safety of biological agents.Management of the pregnant IBD patient.Inflammatory bowel disease and pregnancy: evidence, uncertainty and patient decision-makingIs infliximab safe to use while breastfeeding?Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further EducationGender-related issues in the female inflammatory bowel disease patient.Common Adverse Effects of Anti-TNF Agents on Gestation.
P2860
Q26829392-4BCC0B44-89F7-40F2-8729-C5DC4F27BF5AQ26851451-40C7A026-E6BE-449C-ABB3-5ADA1B6D7141Q26864267-CA810222-4EA4-4C3F-A6E1-2DF44E0468B7Q26865914-E0160FC3-8DE0-4369-A4AE-9C2F720C9449Q27008090-AAC2B4E9-D0A6-49DB-BEF8-1DBCFDD241FEQ27030762-723243B3-7F7A-4BD1-955A-2A8B45EBAC52Q28218219-44BBCD11-1D77-4C0D-A63F-B411ECB3FEE6Q28294134-F50ACF84-4827-492B-AFA0-0A93542CF599Q31044246-BECE6E2D-678B-4758-A9A4-73ADB1AC19D8Q33623762-25B5CB57-07F5-4B12-9F50-B7C439A209B6Q33819478-3DDE481A-480D-45DB-B95E-D2D2B62C072FQ34152778-FEB1448F-F372-48B4-B145-C3D3B17B7591Q34244877-7067EA0B-FF7F-4318-9667-C42335734674Q34333931-2709060E-2863-46A4-A9C6-727A1AB8D850Q34758793-2C011D8D-1933-47A5-97AF-FC8876D33066Q35193565-FA0FE393-F856-4687-89F6-7E4B69FAE6F4Q35638239-C86FC974-0AB2-4CA3-B3A9-5B81821BFEEFQ35760599-F9E0B153-54B6-4290-AC3F-6FF3387F3E97Q35929544-2ACC6FF6-C904-4BA8-AC09-F2863A60CE1CQ35941677-5C0EC58E-58B5-45C6-A21C-07612F489EAEQ35953861-AA3F1375-648C-4767-A923-8D912CD56F2BQ35973766-A600C829-01ED-45E4-ABF7-B7E1E82F59AEQ36467833-068960FF-68C1-48F7-8941-5D3A2EEA19A7Q36524821-3214500B-0BD4-49E3-B6C4-EC11D26B8605Q36687466-64586D13-2EEA-4072-8F0F-969E34445516Q36711722-D321D7BF-BDC8-4C73-9CC8-CB1E4F8342C1Q36737339-B147BCA5-7987-471A-9C5C-217254717BE9Q36767030-025C9669-4C84-45D7-9FD1-38E5542EE5A9Q36819564-5CB69663-5C63-48E3-B29A-A8E5A6B8071BQ36989959-411DDE28-EDAE-4C11-8C84-345753DC3D75Q37073424-57E58E8B-7B2A-4011-8EB4-21596593E664Q37103320-E2F0D8F3-EB47-4522-93A3-B5E2BB71D3BFQ37149381-CCF73530-AF9A-4977-BA22-F2DEEFD8F98DQ37186057-CDD99DBD-76FF-4033-8371-200AB68A6509Q37216502-0B415C1C-2D74-40E1-AED9-63274B2F58ACQ37224385-B4BF807F-604F-4725-BE0B-4B22A746FBD4Q37265629-66DBB8BE-1370-4130-8489-3DA0E1C89721Q37306723-F3B42DEC-5869-4A91-9BF2-436CCDE19F60Q37436491-23E15C8F-0E1B-4C60-ACAB-587300A1C7C1Q37504096-43A68341-315B-43F4-99E3-7F67D6C612F9
P2860
Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Intentional infliximab use dur ...... remission in Crohn's disease.
@ast
Intentional infliximab use dur ...... remission in Crohn's disease.
@en
type
label
Intentional infliximab use dur ...... remission in Crohn's disease.
@ast
Intentional infliximab use dur ...... remission in Crohn's disease.
@en
prefLabel
Intentional infliximab use dur ...... remission in Crohn's disease.
@ast
Intentional infliximab use dur ...... remission in Crohn's disease.
@en
P2093
P2860
P1476
Intentional infliximab use dur ...... remission in Crohn's disease.
@en
P2093
Mahadevan U
Sandborn WJ
Terdiman JP
P2860
P304
P356
10.1111/J.1365-2036.2005.02405.X
P407
P577
2005-03-01T00:00:00Z